India's Glenmark May Shelve Research On Metabolic Disorders Due To Tougher Regulatory Standards

Glenmark likely to drop DPP-4 and vanilloid compounds returned by pharma licensors and focus on new outlicensing opportunities, including biologics.

More from India

More from Asia